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Abstract
Background:  Drugs  administered  by  intravenous  routes  may  be  contaminated  during  several
stages of  production  or  preparation.  Sugammadex  is  a  modiﬁed  gamma  cyclodextrin.  While
research  into  the  antibacterial  effects  of  varieties  of  cyclodextrin  is  available,  there  are  no
studies  focusing  on  the  antibacterial  effects  of  sugammadex.  This  study  investigates  the  in  vitro
antimicrobial  activity  of  sugammadex.
Materials  and  methods: The  in  vitro  antimicrobial  activity  of  sugammadex  was  investigated
using the  broth  microdilution  method.  The  pH  of  the  test  solution  was  determined  using  a
pH  meter.  The  test  microorganisms  included  Staphylococcus  aureus  ATCC  29213,  Enterococcus
fecalis  ATCC  29212,  Escherichia  coli  ATCC  25922  and  Pseudomonas  aeruginosa  ATCC  27853.  In
the  second  phase  of  the  study  100  mg/mL  sugammadex  (50  g)  was  contaminated  with  test
microorganisms  (50  g),  including  S.  aureus  ATCC  29213,  E.  fecalis  ATCC  29212,  E.  coli  ATCC
25922  and  P.  aeruginosa  ATCC  27853,  left  to  incubate  for  24  h  and  then  the  bacterial  production
in  sugammadex  was  evaluated.
Results: The  pH  of  the  test  solutions  ranged  between  7.25  and  6.97.  Using  the  microdilution
method, sugammadex  had  no  antibacterial  effect  on  S.  aureus,  E.  fecalis,  E.  coli  and  P.  aerugin-
osa  at  any  concentration.  In  the  second  phase  of  the  study  bacterial  production  was  observed
after  24  h  in  100  mg/mL  sugammadex  contaminated  with  the  test  microorganisms  S.  aureus,  E.
fecalis,  E.  coli  and  P.  aeruginosa.
Conclusions: Sugammadex  had  no  antimicrobial  effect  on  the  test  microorganisms,  S.  aureus,  E.
fecalis,  E.  coli  and  P.  aeruginosa.  Care  should  be  taken  that  sterile  conditions  are  maintained  in
the  preparation  of  sugammadex;  that  the  same  sugammadex  preparation  not  be  used  for  more
than  one  patient;  and  that  storage  conditions  are  adhered  to  after  sugammadex  is  put  into  the
injector.
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Table  1  The  pH  values  of  tested  dilutions  of  sugammadex.
Dilution  of  sugammadex  (g/mL)  pH
512  g/mL  7.25
256  g/mL 7.22
128 g/mL 7.14
64 g/mL  7.09
32  g/mL  7.04
16  g/mL  7.04
8  g/mL  7
4  g/mL  6.99
2  g/mL  6.98
1  g/mL 6.97
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ntroduction
ome  anesthetic  agents  such  as  propofol  are  known  to
upport the  growth  of  microorganisms,1--5 while  other
nesthetic agents  such  as  morphine  sulphate,  thiopental
odium, fentanyl  citrate,  dexmedetomidine  and  midazo-
am inhibit  microbial  growth.3--7 Anesthetic  agents  may  be
ontaminated by  microorganisms  at  various  stages  during
reparation for  use.2 It  is  important  for  this  reason  that  the
ntibacterial properties,  or  the  ability  to  enhance  bacterial
roduction, of  anesthetic  agents  in  a  contaminated  situation
e known.8
Sugammadex  is  a  modiﬁed  gamma  cyclodextrin.9--11
yclodextrins  are  water  soluble  cyclic  oligosaccharides
ith a  lipophilic  core.  Sugammadex  has  quickly  found  a
lace in  clinical  use  as  a  selective  neuromuscular  blockade
everser.9--11 Sugammadex  quickly  encapsulates  steroidal
euromuscular blockers,  increasing  the  amount  of  encap-
ulated steroidal  neuromuscular  blockers  in  plasma  and
eparating the  blockers  from  the  nicotinic  acetylcholine
eceptors.9--11
Cyclodextrins  are  molecules  that  are  often  used  in
he food  and  pharmaceutical  industries.  They  are  com-
only used  to  convert  lipophilic  medications  to  hydrophilic
orms. Other  applications  of  cyclodextrins  include  the  ﬁeld
f microbiology.  Some  cyclodextrins,  such  as  dimethyl-b-
yclodextrin, have  been  used  to  increase  production  of
elicobacter pylori,12 while  others,  like  hydroxypropyl-
-cyclodextrin,  have  been  reported  to  prevent  bacterial
roduction when  used  to  coat  vascular  prostheses.13
owever  there  are  no  studies  evaluating  the  effect  of  sug-
mmadex, a  modiﬁed  gamma  cyclodextrin  molecule  lately
eing used  in  anesthesiology,  on  bacterial  production.
The  aim  of  this  study  was  to  evaluate  the  antimicrobial
ffects of  sugammadex  on  the  test  microorganisms.  The  test
icroorganisms chosen  were  Staphylococcus  aureus  Amer-
can Type  Culture  Collection  (ATCC)  29213,  Enterococcus
ecalis ATCC  29212,  Escherichia  coli  ATCC  25922  and  Pseu-
omonas aeruginosa  ATCC  27853.
aterials and methods
he  antibacterial  activity  of  sugammadex  was  investigated
sing the  broth  microdilution  method  according  to  the  pro-
edures outlined  by  the  Clinical  and  Laboratory  Standards
nstitute (CLSI).14
Brieﬂy,  sugammadex  was  diluted  with  0.9%  sterile
aline to  ﬁnal  concentrations  of  512  g/mL,  256  g/mL,
28 g/mL,  64  g/mL,  32  g/mL,  16  g/mL,  8  g/mL,
 g/mL,  2  g/mL,  1  g/mL  and  0.5  g/mL.  For  each  neu-
omuscular blocking  drug,  the  pH  values  of  all  the  dilutions
ere determined  with  a  pH  meter  (Sartorius  pH  Meter  PB-
1). S.  aureus  ATCC  29213,  E.  fecalis  ATCC  29212,  E.  coli
TCC 25922  and  P.  aeruginosa  ATCC  27853  were  used  as  con-
rol microorganisms.  The  bacteria  (5  ×  105 colony-forming
nits per  milliliter;  (CFU/mL)),  MHB  (Mueller--Hilton  broth)
nd the  sugammadex  in  the  speciﬁed  concentrations  were
ncubated in  wells  on  microplates  at  35 ◦C  for  20  h.  The
inimal inhibitory  concentrations  (MIC)  were  determined
y observing  the  lowest  concentration  of  the  agent  that
C
f
u
C0.5  g/mL 6.97
Physiological serum  0.9%  6.8
nhibited  visible  growth  of  the  bacterium.  Haze  or  turbidity
n the  wells  was  an  indicator  of  bacterial  growth.
In  the  second  stage  of  the  study  100  mg/mL  sugammadex
as contaminated  with  the  test  organisms,  S.  aureus  ATCC
9213, E.  fecalis  ATCC  29212,  E.  coli  ATCC  25922  and  P.  aeru-
inosa  ATCC  27853.  Bacteria,  50  L  (5  ×  105 colony-forming
nits per  milliliter;  (CFU/mL)),  and  50  L  sugammadex
100 mg/mL)  were  incubated  at  35 ◦C  for  24  h.  After  24  h  the
acterial production  in  the  sugammadex  was  evaluated.
esults
sing  the  microdilution  technique,  sugammadex  had  no
ntibacterial effect  on  S.  aureus,  E.  fecalis,  E.  coli  and  P.
eruginosa at  any  concentration.
In  the  second  part  of  the  study,  after  24  h  incubation
00 mg/mL  sugammadex  contaminated  with  S.  aureus,  E.
ecalis,  E.  coli  and  P.  aeruginosa,  bacterial  growth  was
bserved.
The pH  of  the  test  solutions  ranged  between  7.25  and
.97. The  pH  values  are  listed  in  Table  1.
iscussion
n  this  study,  we  found  that  sugammadex  does  not  have
ntimicrobial properties  with  regard  to  the  test  organisms,
. aureus,  E.  fecalis,  E.  coli  and  P.  Aeruginosa.
Drugs  manufactured  for  intravenous  use  should  be  pre-
ared and  administered  in  sterile  conditions.  Infectious
icroorganisms can  be  introduced  into  the  patient  through
ontaminated containers,  rubber  diaphragms,  needles  and
nfusion sets.
Anesthetic agents  may  be  contaminated  by  microorgan-
sms during  preparation.  For  this  reason,  the  antimicrobial
ffects of  the  used  agents  are  important.8 It  is  known  that
ropofol supports  the  growth  of  microorganisms.2--4,7,8,15--18
n  the  other  hand,  morphine  sulphate,  thiopental  sodium,
entanyl citrate,  dexmedetomidine,  atracurium,  rocuro-
ium and  midazolam  have  antimicrobial  effects.3,5--8
Sugammadex  is  a  modiﬁed  gamma  cyclodextrin.9--11yclodextrins  are  molecules  that  are  often  used  in  the
ood and  pharmaceutical  industries.  They  are  commonly
sed to  convert  lipophilic  medications  to  hydrophilic  forms.
yclodextrins are  water  soluble  cyclic  oligosaccharides  with
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2Antimicrobial  features  of  sugammadex  
a  lipophilic  core.  Other  applications  of  cyclodextrins  include
the ﬁeld  of  microbiology.  Some  cyclodextrins,  such  as
dimethyl-b-cyclodextrin, have  been  used  to  increase  pro-
duction of  H.  pylori.12 When  added  to  agar  gels  cyclodextrins
such as  alpha-  and  beta-cyclodextrin/hexadecane  are  suit-
able foodbeds  for  the  growth  of  microorganisms  such  as
Candida lipolytica  and  C.  tropicalis.19 Research  has  shown
that cyclodextrin  molecules,  such  as  beta-cyclodextrin,
when added  to  liquid  cultures  neutralize  potential  toxic
combinations and  increase  the  growth  of  microorganisms
such as  H.  pylori.20--22 Solid  cultures  including  modiﬁed
cyclodextrins have  been  used  for  selective  isolation  of
microorganisms such  as  Bordetella  pertussis.23--26
However  other  cyclodextrins,  such  as  hydroxypropyl-
b-cyclodextrin,  have  been  reported  to  prevent  bacterial
production when  used  to  coat  vascular  prostheses.13
Previous  studies  have  reported  methyl-beta-cyclodextrins
inhibiting  the  growth  of  bacillus  types.27 Researchers  found
that methyl-beta-cyclodextrins  crossed  the  cell  membranes
of bacillus  species  and  caused  cell  lysis;  however  they
emphasized that  this  activity  was  not  observed  for  other
gram negative  and  positive  bacteria.27 Another  study  found
that cyclodextrin  derivatives  acted  like  antimicrobial  peptid
polymixin B  and  could  inhibit  bacterial  proliferation.28
There  are  no  studies  evaluating  the  effect  of  sugam-
madex, a  modiﬁed  gamma  cyclodextrin  molecule  lately
being used  in  anesthetic  practice,  on  bacterial  production.
In our  study,  we  found  that  sugammadex  did  not  have  antimi-
crobial properties  with  respect  to  the  growth  of  S.  aureus,
E. coli,  P.  aeruginosa  and  E.  fecalis.
Most  bacteria  prefer  a  fairly  narrow  pH  range,  between  6
and 8,  for  survival.3,17 The  growth  of  S.  aureus  (ATCC  25923),
E. coli  (ATCC  25922)  or  P.  aeruginosa  (ATCC  27853)  was  not
affected  by  growth  conditions  with  a  pH  between  5.0  and
8.0.29 The  bactericidal  properties  of  thiopental  are  thought
to be  related  to  its  high  pH.30 Similarly,  the  pH  range  of
midazolam was  shown  to  be  responsible  for  its  bacterial
inhibitory effect.5,7,31 In  our  study,  prior  to  performing  the
recommended dilution,  the  pH  of  sugammadex  was  approx-
imately 7.5.  The  diluted  sugammadex  had  pH  in  a  narrow
range between  6.97  and  7.25.  These  pH  values  are  within  the
range for  proliferation  of  the  test  microorganisms  S.  aureus
(ATCC 25923),  E.  coli  (ATCC  25922)  and  P.  aeruginosa  (ATCC
27853).
In conclusion,  sugammadex  had  no  antibacterial  effect
on S.  aureus,  E.  fecalis,  E.  coli  and  P.  aeruginosa.
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